# A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

> **NCT03973112** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 123 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** HLX10 3mg/kg
- **DRUG:** HLX04 5mg/kg
- **DRUG:** HLX04 10mg/kg

## Key facts

- **NCT ID:** NCT03973112
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-24
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03973112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03973112, "A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03973112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*